Results 111 to 120 of about 4,368 (201)

Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study. [PDF]

Cureus
Otani H, Kurioka S.
europepmc   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD).
Wallbach, Manuel, Hellenkamp, Kristian, Delistefani, Fani, von Haehling, Stephan, Schäfer, Ann‐Kathrin, Kaebe, Sophia, Valentova, Miroslava, Koziolek, Michael J., Gollisch, Katja, Raddatz, Dirk   +9 more
core   +1 more source

Targeting DPP9 attenuates podocyte injury by regulating NRF2 antioxidant signaling. [PDF]

Front Pharmacol
Cui C, Wei S, Zhang J, Xu J, Naimova S, Li Y, Wang H, Wang Y, Si R, Wei L, Lei F, Yu X, Liu P, Fu R.   +13 more
europepmc   +1 more source

Investigating the Compatibility of Weekly Prednisone with Daily Finerenone in Duchenne Muscular Dystrophy Mouse Models

Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin gene, leading to progressive skeletal muscle degeneration, cardiomyopathy, and fibrosis.
Pasupuleti, Surabhi
core  

Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure. [PDF]

JACC Adv
Michos ED, Ambrosy AP, Fonarow GC.
europepmc   +1 more source

Hypokalemia and New-Onset Diabetes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. [PDF]

Diabetes Care
Ostrominski JW, Lu H, Claggett BL, Desai AS, Jhund PS, Henderson AD, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Brinker M, Scalise A, De Sanctis Y, Hofmeister L, McMurray JJV, Solomon SD, Vaduganathan M.   +18 more
europepmc   +1 more source

Letter to the Editor: Finerenone and proteinuria in diabetic kidney disease. [PDF]

World J Nephrol
Raikou VD, Gavriil S.
europepmc   +1 more source

eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes. [PDF]

Diabetes Metab Syndr Obes
Su C, Li X, Wang S, Liu D.
europepmc   +1 more source

Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach. [PDF]

World J Nephrol
Jose A, Kamrul-Hasan ABM, Fernandez CJ, Pappachan JM.   +3 more
europepmc   +1 more source

Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE. [PDF]

Kidney Int Rep
Cherney DZI, Yi TW, Heerspink HJL, Ji L, McGill JB, Rossing P, Tuttle KR, Bech JN, Fiorina P, Power A, Schousboe K, Selby NM, Setola E, Smeijer JD, Lawatscheck R, Brinker M, Russell J, Schloemer P, Groop PH, FINE-ONE Investigators23.   +19 more
europepmc   +1 more source